
# MOBITIL JOURNAL


12 Pages

Issue date : Aug 2011 VOL.NO. 1

Medical Union Pharmaceuticals, Abu-Sultan,Ismailia,Egypt.

## THE NSAIDs REPORT

**More and more patients become unsatisfied with ordinary NSAIDs treatment results**

**Condition:** Rheumatoid Arthritis& Joint pain
**Drug:** Ibuprofen
**Reviewer:** Female, 45, on treatment for 3 month
**Comment:** Never had a blood pressure problem until I began taking this drug on a regular basis to control pain/inflammation. This NSAID is definitely not for me!

**Condition:** Osteoarthritis neck and knee
**Drug:** Piroxicam
**Reviewer:** Female, 67, on treatment for 10 years
**Comment:** It worked great as pain killer. But eventually my BP started rising only due to Piroxicam.

**Condition:** Tennis elbow
**Drug:** Diclofenac Pottassium
**Reviewer:** Male, 50, on treatment for less than one month
**Comment:** No relief noticed after 8 days at 3 tablets per day…Very irritating…

**Condition:** Menstrual cramps
**Drug:** Ibuprofen
**Reviewer:** Female, 21, on treatment for 1 day
**Comment:** Triggered my asthma within a day. Severe shortness of breath and constant stabbing pain when taking a slightly deep breath for 3 days after that. Is good for cramps but not so good for people with asthma as it triggers it.

# MOBITIL

## One Step above

AAPS PharmSciTech. 2004 Jul 27;5(4):e59.

**Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.**

Ghorab MM, Abdel-Salam HM, El-Sayad MA, Mekhel MM.
Department of Pharmaceutics, College of Pharmacy, Suez Canal University, Ismailia, Egypt.
mghorab@hotmail.com

**Abstract**

The purpose of this research was to evaluate beta-cyclodextrin (beta-CD) as a vehicle, either singly or in blends with lactose (spray-dried or monohydrate), for preparing a meloxicam tablet. Aqueous solubility of meloxicam in presence of beta-CD was investigated. The tablets were prepared by direct compression and wet granulation techniques. The powder blends and the granules were evaluated for angle of repose, bulk density, compressibility index, total porosity, and drug content. The tablets were subjected to thickness, diameter, weight variation test, drug content, hardness, friability, disintegration time, and in vitro dissolution studies. The effect of beta-CD on the bioavailability of meloxicam was also investigated in human volunteers using a balanced 2-way crossover study. Phase-solubility studies indicated an A(L)-type diagram with inclusion complex of 1:1 molar ratio. The powder blends and granules of all formulations showed satisfactory flow properties, compressibility, and drug content. All tablet formulations prepared by direct compression or wet granulation showed acceptable mechanical properties. The dissolution rate of meloxicam was significantly enhanced by inclusion of beta-CD in the formulations up to 30%. The mean pharmacokinetic parameters (C(max), K(e), and area under the curve [AUC](0-infinity)) were significantly increased in presence of beta-CD. These results suggest that beta-CD would facilitate the preparation of meloxicam tablets with acceptable mechanical properties using the direct compression technique as there is no important difference between tablets prepared by direct compression and those prepared by wet granulation. Also, beta-CD is particularly useful for improving the oral bioavailablity of meloxicam.

**MOBITIL improved oral bioavailablity**

Meloxicam and ß - Cyclodextrin

**Tablet Formulation Containing Meloxicam and ß - Cyclodextrin: Mechanical Characterization and Bioavailability Evaluation**

Mamdouh M. Ghorab, Heba M. Abdel-Salam, Marwa A. El-Sayad and Mohammed M. Mekhel
Department of Pharmaceutics, College of Pharmacy, Suez Canal University, Ismailia, Egypt
Research Projects Department, Medical Union Pharmaceutical Co, Abu Sultan-Ismailia, Egypt
Submitted: March 22, 2004; Accepted: July 27, 2004.

In conclusion, inclusion complexation of MX in ß-CD results not only in an improvement of the bioavailability of the drug but also in the rapid plasma appearance of the drug observed for the complex, which would be highly advantageous for the use of this form in oral MX therapy. Furthermore, the use of ß-CD would facilitate the pharmaceutical preparation of the tablets, particularly from the viewpoint of enhancement of the dissolution rate and compression behavior, which give good mechanical properties when used as a direct compression vehicle.




**Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs**

**Meloxicam seems to be well tolerated by NSAID-sensitive subjects whose reactions are manifested by urticaria/angioedema. Additional study is needed for a more complete assessment of its tolerability in patients with aspirin-induced asthma and other severe manifestations of NSAID sensitivity.**

Ann Allergy Asthma Immunol. 2000 Jun;84(6):613-7.

# MOBITIL Comparable Efficacy & Safety




**Meloxicam 7.5mg has the same efficacy of Diclofenac Sodium 100mg in treatment of Osteoarthritis with a better safety profile.**

In December 2009, the FDA issued a warning about the **potential for liver damage during treatment with all diclofenac products, including the gel.** The smallest effective amount should be applied for the shortest time possible to minimize the potential for an adverse liver-related event.

Meloxicam in Osteoarthritis: A 6-Month, Double-Blind Comparison with Diclofenac Sodium

Oxford Journals Medicine Rheumatology Volume35, Issue suppl1Pp.39-43